Browsing by Subject "BRCA mutations"
Now showing items 1-1 of 1
-
A review on newly approved PARP inhibitors: Talazoparib and Olaparib
(Brac University, 2024-01)This review delves into the intricate landscape of Poly ADP-ribose polymerase (PARP) inhibitors, specifically focusing on two notable contenders in cancer therapy – Talazoparib and Olaparib. By targeting the DNA Damage ...